A 5-aza-2?-deoxycytidine/valproate combination induces cytotoxic T-cell response against mesothelioma Source: Eur Respir J 2011; 38: 1105-1116 Year: 2011
Comparison of anticancer effects of a novel histone deacetylase (HDAC) inhibitor CG200745 and SAHA in non-small lung cancer cells Source: International Congress 2019 – Diagnostic procedures and biology of lung cancer Year: 2019
Valproate–doxorubicin: promising therapy for progressing mesothelioma. A phase II study Source: Eur Respir J 2011; 37: 129-135 Year: 2011
Histone deacetylase inhibition promotes fibroblast apoptosis and ameliorates pulmonary fibrosis in mice Source: Eur Respir J 2014; 43: 1448-1458 Year: 2014
ONX0912, a novel proteasome inhibitor for the treatment of lung fibrosis? Source: Annual Congress 2012 - New drug targets and pre-clinical models for respiratory diseases Year: 2012
Histone deacetylase inhibition significantly augments human mesothelioma cellular response to chemotherapeutic agents Source: Eur Respir J 2001; 18: Suppl. 33, 396s Year: 2001
Prevention of fetal programming of pulmonary vascular dysfunction by a histone deacetylase inhibitor Source: Annual Congress 2010 - Experimental pulmonary hypertension Year: 2010
Oleanolic acid acetate ameliorates bleomycin-induced pulmonary fibrosis through inhibition of epithelial-mesenchymal transition Source: International Congress 2019 – Translational aspects of idiopathic pulmonary fibrosis Year: 2019
LSC Abstract – Histone deacetylase 7 mediated metabolic remodeling: A new crosslink between pulmonary hypertension and cancer Source: International Congress 2016 – The nature of pulmonary hypertension Year: 2016
SIRT1, a histone deacetylase, regulates matrix metalloproteinase-9 expression Source: Annual Congress 2005 - Pulmonary hypertension and fibrosis: novel mechanisms Year: 2005
Histone deacetylase inhibitor panobinostat reduces hypoxia-related cisplatin resistance in NSCLC cells by HDAC-mediated Hifalpha destabilization Source: Annual Congress 2013 –Basic research on lung cancer Year: 2013
RF22c, a 5-lipoxygenase inhibitor, in monocrotaline-induced PAH Source: International Congress 2019 – Pulmonary hypertension with lung diseases and experimental pulmonary hypertension Year: 2019
Steroids and histone deacetylase in ventilation-induced gene transcription Source: Eur Respir J 2007; 30: 865-877 Year: 2007
Targeting fatty acid amide hydrolase as a therapeutic strategy for antitussive therapy Source: Eur Respir J, 50 (3) 1700782; 10.1183/13993003.00782-2017 Year: 2017
Single and combined effects of cisplatin, sodium butyrate and sirtinol on covalent histone modifications in human cell lines Source: Eur Respir J 2007; 30: Suppl. 51, 146s Year: 2007
Roflumilast N-oxide, a PDE4 inhibitor, curbs bleomycin-induced lung fibroblast activation in vitro Source: Annual Congress 2011 - Airway smooth muscle cells and fibroblasts: cell biology Year: 2011
Anti-inflammatory therapy in cystic fibrosis: a comparative study in the treatment with nimesulide (selective cyclooxygenase-2 inhibitor) and clarithromycin (14-membered ring macrolide antibiotic) Source: Eur Respir J 2004; 24: Suppl. 48, 615s Year: 2004
Histone deacetylase activity is reduced in COPD. Modulation by theophylline Source: Eur Respir J 2003; 22: Suppl. 45, 4s Year: 2003
Differential actions of the endogenous docosahexaenoic acid (DHA) electrophilic derivative 17-oxo-DHA in macrophages and bronchial epithelial cells Source: Annual Congress 2013 –The pulmonary epithelium: recent developments Year: 2013
Involvement of coactivator associated arginine methyltransferase 1 (CARM1) in development of elastase-induced progressive emphysema Source: Annual Congress 2013 –Novel mechanisms in lung injury Year: 2013